#1 Clinical Trials Search in Europe

Gen3017

GEN3017, also known as DuoBody-CD3xCD30, is an innovative drug currently undergoing clinical trials for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. This article provides an overview of the ongoing Phase 1/2a trial, which aims to evaluate the safety, efficacy, and potential benefits of GEN3017 for patients with these challenging conditions.

Table of Contents

What is GEN3017?

GEN3017, also known as DuoBody-CD3xCD30, is a new investigational drug being developed for the treatment of certain types of blood cancers[1]. It is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with specific types of lymphoma.

What conditions does GEN3017 treat?

GEN3017 is being studied for the treatment of two main types of lymphoma[1]:

  • Hodgkin lymphoma (HL): A type of cancer that starts in the lymphatic system, particularly affecting a type of white blood cell called lymphocytes.
  • Non-Hodgkin lymphoma (NHL): A group of blood cancers that also start in the lymphatic system but can be more varied in their characteristics and behavior than Hodgkin lymphoma.

Specifically, the drug is being tested in patients with relapsed or refractory forms of these lymphomas. This means the cancer has either returned after initial treatment (relapsed) or has not responded well to previous treatments (refractory)[1].

How does GEN3017 work?

GEN3017 is a type of drug called a bispecific antibody. It is designed to target two specific proteins[1]:

  • CD3: A protein found on T cells, which are a type of immune cell.
  • CD30: A protein often found on the surface of lymphoma cells.

By targeting both of these proteins, GEN3017 aims to bring T cells (part of the body’s immune system) close to the lymphoma cells, potentially helping the immune system to recognize and attack the cancer cells more effectively[1].

Current Clinical Trial

GEN3017 is currently being studied in a Phase 1/2a clinical trial. This type of trial is designed to evaluate both the safety of the drug and gather initial data on its effectiveness[1].

The trial is divided into two main parts:

  1. Dose Escalation Phase: This part aims to determine the safest and most effective dose of GEN3017.
  2. Expansion Phase: This part will further evaluate the effectiveness of GEN3017 at the dose determined in the first phase.

Who is eligible for the trial?

The trial has specific criteria for who can participate. Some key eligibility factors include[1]:

  • Age: Participants must be at least 18 years old in most locations. In the United States and Australia, participants as young as 16 may be eligible for certain parts of the study.
  • Diagnosis: Participants must have a confirmed diagnosis of relapsed or refractory classical Hodgkin lymphoma or certain types of non-Hodgkin lymphoma.
  • Previous treatments: Participants must have received at least 2 or 3 prior lines of therapy, depending on their specific situation.
  • CD30 positivity: The participant’s cancer must test positive for the CD30 protein.
  • General health: Participants must be in relatively good overall health, as measured by specific performance scales.

There are also several factors that might exclude someone from participating, such as certain previous treatments or other health conditions[1].

What are the objectives of the trial?

The main objectives of the trial include[1]:

  • Determining the safest and most effective dose of GEN3017
  • Evaluating the safety and tolerability of the drug
  • Assessing how well GEN3017 works against the cancer (its anti-tumor activity)
  • Studying how the drug moves through and is processed by the body (pharmacokinetics)
  • Evaluating whether the body develops an immune response to the drug (immunogenicity)

How is GEN3017 administered?

GEN3017 is given as a subcutaneous injection. This means it is injected just under the skin, rather than into a vein[1]. The exact dosing schedule will be determined as part of the clinical trial.

Safety Considerations

As with any investigational drug, the safety of GEN3017 is a primary focus of the clinical trial. The researchers will be closely monitoring for any side effects or adverse reactions throughout the study[1].

It’s important to note that because GEN3017 is still in the early stages of testing, not all potential side effects may be known. Patients considering participating in the trial should discuss the potential risks and benefits thoroughly with their healthcare provider[1].

Aspect Details
Drug Name GEN3017 (DuoBody-CD3xCD30)
Trial Phase Phase 1/2a
Conditions Studied Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Main Objectives Determine safe dosing, evaluate safety and tolerability, assess preliminary anti-tumor activity
Administration Route Subcutaneous injection
Key Eligibility Criteria CD30-positive tumors, prior treatment history, measurable disease
Primary Endpoints Dose-limiting toxicities, adverse events, objective response rate
Secondary Endpoints Pharmacokinetics, immunogenicity, duration of response, progression-free survival

FAQ

  • What is GEN3017? GEN3017, also known as DuoBody-CD3xCD30, is an investigational drug being studied for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. It is a protein-based medication that targets specific molecules on cancer cells.
  • What is the purpose of the clinical trial for GEN3017? The clinical trial aims to determine the safety, effectiveness, and proper dosing of GEN3017 in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. It includes both a dose escalation phase and an expansion phase to gather comprehensive data on the drug's performance.
  • Who is eligible to participate in the GEN3017 clinical trial? Eligible participants must have confirmed relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma, be at least 18 years old (16 years old in some locations), have measurable disease, and meet specific performance status criteria. They must also have CD30-positive tumors and have received prior treatments for their condition.
  • How is GEN3017 administered in the clinical trial? GEN3017 is administered as a concentrate for solution for injection, given subcutaneously (under the skin). The trial involves multiple treatment cycles, with specific dosing determined during the dose escalation phase of the study.
  • What are the main outcomes being measured in the GEN3017 trial? The trial is measuring several outcomes, including the safety profile of GEN3017, its effectiveness in shrinking tumors (objective response rate), how long the responses last, and how quickly patients respond to treatment. The study also looks at the drug's behavior in the body (pharmacokinetics) and whether patients develop antibodies against the drug.

Ongoing Clinical Trials on Gen3017

  • Study on the Safety and Effectiveness of GEN3017 for Patients with Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Italy The Netherlands

Glossary

  • Relapsed or Refractory: Relapsed means the cancer has returned after a period of improvement, while refractory means the cancer has not responded to treatment or has stopped responding.
  • Hodgkin Lymphoma: A type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
  • Non-Hodgkin Lymphoma: A group of blood cancers that includes all types of lymphoma except Hodgkin lymphoma. It starts in the lymphatic system.
  • CD30: A protein found on some cancer cells, particularly in certain lymphomas, which can be targeted by specific treatments.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined to be appropriate for further testing in Phase 2 clinical trials.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Immunogenicity: The ability of a substance to provoke an immune response in the body.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gen3017-for-patients-with-relapsed-or-refractory-hodgkin-and-non-hodgkin-lymphoma/